Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • NPPA fixes retail...

    NPPA fixes retail price of 5 formulations

    Written by Ruby Khatun Khatun Published On 2018-01-24T11:00:22+05:30  |  Updated On 24 Jan 2018 11:00 AM IST
    NPPA fixes retail price of 5 formulations

    New Delhi: National drug pricing regulator NPPA said it has fixed the retail prices of five formulations including those used for the treatment of hypertension, asthma and heart failure.


    The National Pharmaceutical Pricing Authority (NPPA) has also revised the ceiling price of Metronidazole injection used for the treatment of the bacterial infections.


    "NPPA has fixed/revised ceiling prices/retail prices of 06 formulations under Drugs Prices Control Order, 2013," the regulator said in a notification.


    The NPPA is mandated to fix/revise the prices of controlled bulk drugs and formulations and to enforce prices and availability of the medicines in the country.


    It also monitors the prices of decontrolled drugs in order to keep them at reasonable levels.

    The regulator implements and enforces the provisions of the Drugs (Prices Control) Order.

    It is also entrusted with the task of recovering amounts overcharged by manufacturers for the controlled drugs from the consumers.


    Following are the details






























































    Sl. NoName of the
    Scheduled
    Formulation /Brand Name
    StrengthUnitManufacturer & Marketing
    Company
    Retail
    Price (Rs.)
    (1)(2)(3)(4) (5) (6)
    1.Olmesartan Medoxomil + Amlodipine +Hydrochlorothiazide TabletEach film coated tablet contains:
    Olmesartan Medoxomil IP
    40mg Amlodipine Besylate IP eq.
    to Amlodipine 5mg
    Hydrochlorothiazide IP 12.5mg
    1 TabletM/s Akums Drugs and
    Pharmaceutical
    Ltd. / M/s
    Zuventus
    Healthcare Limited
    13.88
    2.Olmesartan
    Medoxomil +
    Amlodipine +
    Hydrochlorothiazide
    Tablet
    Each film coated tablet contains:
    Olmesartan Medoxomil IP
    20mg Amlodipine Besylate IP eq.
    to Amlodipine 5mg
    Hydrochlorothiazide IP 12.5mg
    1 TabletM/s Akums Drugs and
    Pharmaceutical
    Ltd. / M/s
    Zuventus
    Healthcare Limited
    9.15
    3.Tiotropium Bromide
    + Formoterol Fumarate + Ciclesonide Powder for Inhalation
    Each capsule contains: Tiotropium (as
    Tiotropium Bromide Monohydrate) 18mcg Formoterol Fumarate Dihydrate 12mcg Ciclesonide 400mcg
    1
    Capsule
    M/s Lupin Ltd.14.67
    4.Isosobide Dinitrate +
    Hydralazine HCl
    tablet (Sorbitrate HF)
    Each film coated tablet contains:
    Diluted Isosorbide
    Dinitrate eq. to Isosorbide Dinitrate 20mg Hydralazine
    Hydrochloride 37.5mg
    1 TabletM/s Windlas
    Biotech Ltd. / M/s Abbott
    Healthcaere Pvt. Ltd.
    5.61
    5.Olmesartan
    Medoxomil +
    Amlodipine + Tablet
    Each film coated tablet contains:
    Olmesartan Medoxomil IP
    40mg Amlodipine Besylate IP eq.
    to Amlodipine 5mg
    1 TabletM/s Synokem
    Pharmaceuticals Ltd. / M/s
    Zuventus
    Healthcare Limited
    12.87
































    Sl. No.Name of the
    Scheduled
    Formulation
    Dosage form & StrengthUnitCeiling
    Price(Rs.)
    Review Order
    number and date
    Existing SO number
    and date
    (1) (2)(3) (4) (5) (6) (7)
    1.MetronidazoleInjection 500mg/100ml1 ML0.1214031015/22/2017-
    Pricing dated
    24.8.2017
    2058(E) dated 30.6.2017
    (at Sl. No. 398

    Below are the attachments for the same.


    http://www.nppaindia.nic.in/ceiling/press23jan18/Formulation_Prices(5).pdf


    http://www.nppaindia.nic.in/ceiling/press23jan18/Formulation_Prices(1).pdf


    Medical Dialogues had earlier reported that NPPA had fixed/revised ceiling prices/Retail Prices of 33 formulations under DPCO 2013 exclusive of goods and services tax (GST).


    Read also: NPPA fixes ceiling prices of 33 more drugs, check out details

    5 formulationsasthmabacterial infectionsbulk drugsceiling priceDrugs Prices Control Orderfixesheart failurehypertensionMetronidazole injectionNational Pharmaceutical Pricing AuthorityNPPAretail price
    Source : With PTI inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok